Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Maria-Victoria Mateos-MantecaSophie RigaudeauSupratik BasuIvan SpickaRik SchotsTomasz WrobelGordon CookMeral BeksacKatharine S GriesAnupa KudvaBrenda TrompRian Van RampelberghHuiling PeiSusan WroblewskiRobin CarsonMaria DelioukinaDarrell WhitePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479/NCT02252172.